Baxter Says Generic Co. Infringed Hypertension Med Patent
In its complaint, Deerfield, Ill.-based Baxter alleges Paramus, N.J.-based HQ's submission to the Food and Drug Administration of a new drug application for a generic version of Brevibloc constitutes infringement of its U.S. Patent Numbers 6,310,094 and 6,528,540.
"Baxter has no adequate remedy at law for HQ Specialty...
To view the full article, register now.